[EN] 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER [FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDROQUINOLINE SERVANT D'INHIBITEURS DE L'ACTIVATION DE YAP/TAZ-TEAD POUR LE TRAITEMENT DU CANCER
[EN] 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER [FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDROQUINOLINE SERVANT D'INHIBITEURS DE L'ACTIVATION DE YAP/TAZ-TEAD POUR LE TRAITEMENT DU CANCER
an effective means to convert methyl 2‐(azidomethyl)‐3‐arylpropenoates and 2‐(azidomethyl)‐3‐arylacrylonitriles to the corresponding iminyl radicals via α‐hydrogenabstraction and subsequent extrusion of dinitrogen. Thus formed iminyl radicals then undergo intramolecular ortho attack on the aryl ring, affording methyl quinoline‐3‐carboxylates and quinoline‐3‐carbonitriles respectively.
Ru(III)-catalyzed construction of variously substituted quinolines from 2-aminoaromatic aldehydes (ketones) and isoxazoles: Isoxazoles as cyclization reagent and cyano sources
作者:Di Hu、Chao Pi、Wei Hu、Xiliang Han、Yangjie Wu、Xiuling Cui
DOI:10.1016/j.cclet.2021.12.072
日期:2022.8
N-O bond cleavage and fragmentation. Variously substituted (especially 6- or 7-substituted) quinolines could be easily afforded. This procedure features wide functional group compatibility, efficiency and avoiding toxic cyano source. Meanwhile, this protocol could be successfully applied to scale-up synthesis. Further chemical transformations of 3-cyanoquinoline could give some valuable skeletons, demonstrating
Pyrazolo[3,4-b]quinolines and their use as antiviral agents
申请人:Sterling Drug Inc.
公开号:US04920128A1
公开(公告)日:1990-04-24
Pyrazolo[3,4-b]quinolines having the formula ##STR1## where R is hydrogen, hydroxy or alkoxy; R.sub.2 is halogen, cyano, carbamyl, carboxy, lower-alkylcarbonyl, amino or aminomethyl; and R.sub.1 is hydrogen or selected substituents as defined herein, are useful as antiviral agents and/or as vasodilators.
This invention provides a compound of Formula 1
where Ar, X, R
1
, R
2
, R
3
, and R
4
are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.